<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516437</url>
  </required_header>
  <id_info>
    <org_study_id>116021</org_study_id>
    <nct_id>NCT01516437</nct_id>
  </id_info>
  <brief_title>A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD</brief_title>
  <official_title>A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD) Aged Between 45-75 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The present study aims to assess the natural immunity to specific microbial antigens in
      healthy subjects and in subjects with stable COPD aged between 45-75 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">December 20, 2012</completion_date>
  <primary_completion_date type="Actual">June 28, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-protein D Antibody Concentrations</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-protein D Antibody Concentrations</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pneumolysin Antibody Concentrations</measure>
    <time_frame>At Day 0</time_frame>
    <description>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pneumolysin Antibody Concentrations</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations for Serum Protein-D Enzymatic Inhibition</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations for Serum Protein-D Enzymatic Inhibition</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</measure>
    <time_frame>At Day 0</time_frame>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</measure>
    <time_frame>At Month 6</time_frame>
    <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Specific Cluster of Differentiation 8+ (CD8+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Sputum - Culture Testing Results</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Nasopharyngeal Swab - Culture Testing Results</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Oropharyngeal Swab - Culture Testing Results</measure>
    <time_frame>At Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>HNS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy non-smokers aged between 45-75 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy smokers aged between 45-75 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FeCOPD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NFeCOPD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.</description>
    <arm_group_label>HS Group</arm_group_label>
    <arm_group_label>HNS Group</arm_group_label>
    <arm_group_label>NFeCOPD Group</arm_group_label>
    <arm_group_label>FeCOPD Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Swab collection</intervention_name>
    <description>Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).</description>
    <arm_group_label>HS Group</arm_group_label>
    <arm_group_label>HNS Group</arm_group_label>
    <arm_group_label>NFeCOPD Group</arm_group_label>
    <arm_group_label>FeCOPD Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sputum collection</intervention_name>
    <description>Sputum collection at Day 0 and at exacerbation visits (COPD subjects)</description>
    <arm_group_label>NFeCOPD Group</arm_group_label>
    <arm_group_label>FeCOPD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects (smokers and non-smokers)

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  A male or female between, and including 45 and 75 years of age at the time of consent.

          -  Written informed consent obtained from the subject.

          -  Baseline post-bronchodilator Forced Expiratory Volume of air in one second (FEV1) &gt;
             85% of predicted normal values and baseline post-bronchodilator FEV1/Forced expiratory
             Vital Capacity (FVC) &gt; 70% of predicted normal values.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Non-smokers: subjects who never smoked OR

          -  Smokers: current smoker having a smoking history ≥ 10 pack-years.

        COPD subjects (frequent and non-frequent exacerbators)

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  A male or female between, and including 45 and 75 years of age at the time of consent.

          -  Written informed consent obtained from the subject.

          -  Baseline post-bronchodilator FEV1 &lt; 80% and &gt;30% of predicted normal values and
             baseline post-bronchodilator FEV1/FVC &lt; 70% of predicted normal values.

          -  Current or former smoker having a smoking history of ≥ 10 pack-years.

          -  Documented history of ≥ one exacerbation within 365 days prior to the screening visit
             that required treatment with systemic corticosteroids or resulted in hospitalization.

        Exclusion Criteria:

        Healthy subjects (smokers and non-smokers)

          -  Use of any investigational or non-registered product within 30 days prior to Screening
             Visit or planned use during the study.

          -  Concurrently participating in another clinical study in which the subject has been or
             will be exposed to an investigational or a non-investigational product.

          -  Any known clinically significant anaemia or any other condition as per medical records
             that would preclude the drawing of blood as described in the protocol.

          -  Receipt of any vaccine within 30 days preceding blood sampling.

          -  Previous vaccination with any NTHi vaccine.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             180 days prior to screening visit. Topical steroids are allowed.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including
             human immunodeficiency virus (HIV) infection, based on medical history and physical
             examination.

          -  Serious chronic disease including any medically significant chronic pulmonary,
             cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined
             by medical history and physical examination.

          -  Any known respiratory disorders.

          -  Acute disease and/or fever at the time of the Screening Visit or Visit 1, as
             applicable

          -  Receipt of immunoglobulins and/or any blood products within 90 days prior to Screening
             Visit.

          -  Receipt of interferon within 90 days prior to Screening Visit.

          -  History of malignancy.

          -  Subjects with a history of, or current, alcohol or substance abuse.

          -  Known history of immune-mediated disorder.

          -  Recent use of antibiotics or antiviral drug within 30 days prior to Screening Visit.

          -  Pregnant female.

          -  Other conditions that the investigator judges may interfere with study findings.

        COPD subjects (frequent and non-frequent exacerbators)

          -  Use of any investigational or non-registered product within 30 days prior to Screening
             Visit or planned use during the study. Use of investigational inhaled long acting
             muscarinic antagonists (LAMA), inhaled long acting beta agonists (LABA) or inhaled
             corticosteroids is allowed.

          -  Concurrently participating in another clinical study in which the subject has been or
             will be exposed to an investigational or a non-investigational product. Subjects
             participating in clinical studies with investigational inhaled LAMA and/or LABA and/or
             inhaled corticosteroids can be enrolled.

          -  Any known clinically significant anaemia or any other condition as per medical records
             that would preclude the drawing of blood as described in the protocol.

          -  Receipt of any vaccine within 30 days preceding blood sampling.

          -  Previous vaccination with any NTHi vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including
             human immunodeficiency virus (HIV) infection, based on medical history and physical
             examination.

          -  Serious, uncontrolled disease likely to interfere with the study findings.

          -  Acute disease and/or fever at the time of the Screening Visit or Visit 1, as
             applicable

          -  Receipt of immunoglobulins and/or any blood products within 90 days prior to Screening
             Visit.

          -  Receipt of interferon within 90 days prior to Screening Visit.

          -  History of malignancy.

          -  Subjects with a history of, or current, alcohol or substance abuse.

          -  Known history of immune-mediated disease other than COPD.

          -  Recent use of antibiotics or antiviral drug within 30 days prior to Screening Visit.

          -  Subject who experienced COPD exacerbation which required antibiotic, systemic
             corticosteroid or hospitalisation and which did not resolve at least one month prior
             to Screening Visit and at least 30 days following the last dose of oral
             corticosteroids.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             180 days preceding screening visit.

          -  Subjects with very severe COPD, GOLD stage IV.

          -  Primary diagnosis of asthma.

          -  Other respiratory disorders such as sarcoidosis, tuberculosis, lung cancer, lung
             fibrosis, cystic fibrosis.

          -  A known diagnosis of α-1 antitrypsin deficiency as underlying cause of COPD.

          -  History of lung surgery.

          -  Pregnant female.

          -  Other conditions that the investigator judges may interfere with study findings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary disease (COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. 3 enrolled subjects did not receive subject allocations, and were excluded from the study prior to start.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HNS Group</title>
          <description>Healthy non-smokers aged between 45-75 years</description>
        </group>
        <group group_id="P2">
          <title>HS Group</title>
          <description>Healthy smokers aged between 45-75 years</description>
        </group>
        <group group_id="P3">
          <title>FeCOPD Group</title>
          <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="P4">
          <title>NFeCOPD Group</title>
          <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HNS Group</title>
          <description>Healthy non-smokers aged between 45-75 years</description>
        </group>
        <group group_id="B2">
          <title>HS Group</title>
          <description>Healthy smokers aged between 45-75 years</description>
        </group>
        <group group_id="B3">
          <title>FeCOPD Group</title>
          <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="B4">
          <title>NFeCOPD Group</title>
          <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="10.10"/>
                    <measurement group_id="B2" value="57.8" spread="8.45"/>
                    <measurement group_id="B3" value="64.1" spread="7.39"/>
                    <measurement group_id="B4" value="61.4" spread="6.75"/>
                    <measurement group_id="B5" value="60.26" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-protein D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per millilitre (EU/mL)</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-protein D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="50.2" upper_limit="126.0"/>
                    <measurement group_id="O2" value="66.9" lower_limit="53.1" upper_limit="84.3"/>
                    <measurement group_id="O3" value="61.7" lower_limit="48.3" upper_limit="78.7"/>
                    <measurement group_id="O4" value="72.8" lower_limit="40.1" upper_limit="132.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-protein D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-protein D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="50.2" upper_limit="93.9"/>
                    <measurement group_id="O2" value="61.0" lower_limit="36.6" upper_limit="101.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3786.7" lower_limit="2748.3" upper_limit="5217.5"/>
                    <measurement group_id="O2" value="3400.7" lower_limit="2445.3" upper_limit="4729.4"/>
                    <measurement group_id="O3" value="3323.9" lower_limit="2128.8" upper_limit="5190.1"/>
                    <measurement group_id="O4" value="2563.9" lower_limit="840.5" upper_limit="7821.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Pneumococcal Histidine Triad D Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2521.5" lower_limit="1598.6" upper_limit="3977.4"/>
                    <measurement group_id="O2" value="2160.1" lower_limit="863.2" upper_limit="5405.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pneumolysin Antibody Concentrations</title>
        <description>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumolysin Antibody Concentrations</title>
          <description>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3870.5" lower_limit="2607.0" upper_limit="5746.3"/>
                    <measurement group_id="O2" value="3116.7" lower_limit="2097.3" upper_limit="4631.8"/>
                    <measurement group_id="O3" value="2804.5" lower_limit="1831.8" upper_limit="4293.7"/>
                    <measurement group_id="O4" value="3898.7" lower_limit="1437.4" upper_limit="10574.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pneumolysin Antibody Concentrations</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumolysin Antibody Concentrations</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2275.6" lower_limit="1344.0" upper_limit="3853.0"/>
                    <measurement group_id="O2" value="3222.3" lower_limit="1416.5" upper_limit="7330.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="8.9" upper_limit="12.1"/>
                    <measurement group_id="O2" value="9.3" lower_limit="8.5" upper_limit="10.0"/>
                    <measurement group_id="O3" value="9.9" lower_limit="8.4" upper_limit="11.7"/>
                    <measurement group_id="O4" value="8.9" lower_limit="8.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations for Serum Protein-D Enzymatic Inhibition</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs). The reference seropositivity cut-off value was ≥ 17.8%.</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="8.4" upper_limit="10.4"/>
                    <measurement group_id="O2" value="8.9" lower_limit="8.9" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
          <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
        <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
        <time_frame>At Month 6</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%</title>
          <description>Concentrations were expressed as geometric mean concentrations (GMCs)</description>
          <population>The analysis was performed on the According-to-Protocol cohort at Month 6, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Month 6.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>T cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.6" spread="67.29"/>
                    <measurement group_id="O2" value="163.5" spread="87.11"/>
                    <measurement group_id="O3" value="173.9" spread="89.69"/>
                    <measurement group_id="O4" value="170.1" spread="88.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Specific Cluster of Differentiation 8+ (CD8+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Specific Cluster of Differentiation 8+ (CD8+) T Cells Expressing at Least 2 Markers Among CD 40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α), Interferon-γ (IFN-γ), IL-13 and IL-17 Upon in Vitro Stimulation</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>T cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" spread="56.74"/>
                    <measurement group_id="O2" value="125.2" spread="73.93"/>
                    <measurement group_id="O3" value="125.2" spread="44.12"/>
                    <measurement group_id="O4" value="161.3" spread="43.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Sputum - Culture Testing Results</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Sputum - Culture Testing Results</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moraxella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Nasopharyngeal Swab - Culture Testing Results</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Nasopharyngeal Swab - Culture Testing Results</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moxarella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Oropharyngeal Swab - Culture Testing Results</title>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
        <group_list>
          <group group_id="O1">
            <title>HNS Group</title>
            <description>Healthy non-smokers aged between 45-75 years</description>
          </group>
          <group group_id="O2">
            <title>HS Group</title>
            <description>Healthy smokers aged between 45-75 years</description>
          </group>
          <group group_id="O3">
            <title>FeCOPD Group</title>
            <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
          </group>
          <group group_id="O4">
            <title>NFeCOPD Group</title>
            <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Oropharyngeal Swab - Culture Testing Results</title>
          <population>The analysis was performed on the According-to-Protocol cohort at Day 0, which included all evaluable subjects for whom at least one assay results was available for the blood samples collected at Day 0.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moxarella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bacteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events (SAEs) up to Month 6.</time_frame>
      <desc>Non-serious/frequent adverse events were not collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>HNS Group</title>
          <description>Healthy non-smokers aged between 45-75 years</description>
        </group>
        <group group_id="E2">
          <title>HS Group</title>
          <description>Healthy smokers aged between 45-75 years</description>
        </group>
        <group group_id="E3">
          <title>FeCOPD Group</title>
          <description>COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years</description>
        </group>
        <group group_id="E4">
          <title>NFeCOPD Group</title>
          <description>COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

